Medicus Pharma CEO granted options, 2.94M shares
Medicus Pharma’s CEO received a new stock option grant and a large direct common share award as part of equity compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Medicus Pharma Ltd. (MDCX) reported that Chief Executive Officer and director Raza Bokhari received equity awards on September 4, 2026. He was granted 500,000 stock options to buy Common Shares at an exercise price of $0.1705 per share, expiring on September 4, 2031. These options are scheduled to vest quarterly in four equal installments over one year. On the same date, he also acquired 2,941,176 Common Shares at $0.1705 per share, all held directly, and no Rule 10b5-1 trading plan is reported.
Insights
Analyzing...
Insider Trade Summary
Grant/Award: 3,441,176 shares
Grant/Award
2 txns
Insider
Bokhari Raza
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 500,000 | $0.00 | $0.00 |
| Grant/Award | Common Shares, no par value | 2,941,176 | $0.1705 | $501K |
Holdings After Transaction:
Stock Option (right to buy) — 500,000 contracts (Direct);
Common Shares, no par value — 2,941,176 shares (Direct)
Footnotes (1)
- F1. The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Key Figures
Stock options granted: 500,000 options
Option exercise price: $0.1705 per share
Option expiration date: September 4, 2031
+4 more
7 metrics
Stock options granted
500,000 options
Grant to CEO Raza Bokhari on September 4, 2026
Option exercise price
$0.1705 per share
Exercise price for 500,000 stock options granted September 4, 2026
Option expiration date
September 4, 2031
Expiration of CEO stock option grant
Underlying shares for options
500,000 Common Shares
Shares issuable upon exercise of the granted options
Common Shares acquired
2,941,176 shares
Non-derivative Common Shares granted to CEO on September 4, 2026
Grant price for Common Shares
$0.1705 per share
Price reported for 2,941,176 Common Shares acquired
Common Shares held after transaction
2,941,176 shares
Total direct Common Share holdings of CEO after September 4, 2026 grant
Key Terms
Stock Option (right to buy), exercise price, vesting, expiration date
4 terms
Stock Option (right to buy) financial
"Security title listed as Stock Option (right to buy) for the derivative grant"
exercise price financial
"Conversion or exercise price reported as 0.1705 for the stock options"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option is scheduled to vest quarterly in four equal installments over one year"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"Expiration date of 2031-09-04 reported for the stock option grant"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did MDCX grant to CEO Raza Bokhari on September 4, 2026?
On September 4, 2026, Raza Bokhari received 500,000 stock options with an exercise price of $0.1705 per share and a separate grant of 2,941,176 Common Shares at $0.1705 per share, all reported as directly owned.
What is the vesting schedule for the MDCX stock options granted to the CEO?
The 500,000 stock options granted to the CEO are scheduled to vest quarterly in four equal installments over one year, according to the footnote. The option was granted on September 4, 2026 and vests over the subsequent year.
What is the exercise price and expiration date of the MDCX CEO’s stock options?
The CEO’s stock options have an exercise price of $0.1705 per share and an expiration date of September 4, 2031. Each option is exercisable into one Common Share, subject to the vesting schedule described.
Were the MDCX CEO’s September 4, 2026 transactions under a Rule 10b5-1 plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as affirming a trading plan, and there is no footnote stating that these awards were made pursuant to a Rule 10b5-1 or similar pre-arranged trading plan.
Are the MDCX CEO’s stock options reported as direct or indirect ownership?
The 500,000 stock options are reported as direct ownership, with total derivative securities following the transaction shown as 500,000. The nature of ownership field does not indicate any trust or entity holding for these options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
